EVE Health Group Limited (EVE) AI Stock Analysis

• Market Cap: AU$5.41M
• Dividend Yield: N/A
• Average Volume (3M): 774.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.17
• Revenue Growth: -18.70%
• EPS Growth: 20.83%
• Country: AU
• Employees: 3
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): >-0.01
• Shares Outstanding: 284,876,600
• 10 Day Avg. Volume: 491,958
• 30 Day Avg. Volume: 774,070
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.22
• Price to Sales (P/S): 2.49
• P/FCF Ratio: -2.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: AU$0.02 ▼(-5.00% Downside)

EVE Health Group Limited's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and profitability issues. Technical analysis indicates bearish trends, and valuation metrics are unattractive due to negative earnings. The absence of earnings call insights and corporate events further limits the score.

Positive Factors

Low leverage

A debt-to-equity of 0.03 indicates minimal financial leverage, reducing interest and refinancing risk. For a small, loss-making business this conservative capital structure preserves flexibility to support operations, absorb shocks, and fund strategic moves without heavy borrowing over months.

Free cash flow improvement

Improving free cash flow trends and an FCF/net income ratio of 1.0 suggest cash generation aligning with reported profits. Over a multi-month horizon, stronger FCF supports working capital, limits external financing needs, and provides a foundation for operational stabilization or targeted reinvestment.

Stable equity base

A stable equity ratio provides a solvency buffer and lowers insolvency risk during cyclical or execution setbacks. This durable capital base supports ongoing operations and gives management a longer runway to address structural revenue or margin issues without immediate balance-sheet distress.

Negative Factors

Declining revenues

Sustained top-line contraction undermines scale economics and revenue predictability. Over a 2-6 month horizon, declining sales compress gross throughput, make fixed costs harder to cover, reduce investment capacity, and make margin recovery and profitable growth materially more difficult to achieve.

Persistent unprofitability

Ongoing negative net margins and a negative ROE indicate the business isn’t generating returns on capital. Structurally, this limits internal funding for growth, risks shareholder dilution if capital is raised, and signals deeper operating model issues that must be resolved for durable profitability.

Weak operating cash flow

Negative operating cash flow and poor cash conversion signal earnings quality and liquidity strain. Over several months this forces reliance on external financing or capital management actions, reducing strategic flexibility and increasing execution risk while margins and revenues are under pressure.

EVE Health Group Limited Business Overview & Revenue Model

Company Description

Eve Health Group Limited, together with its subsidiaries, engages in the production and distribution of nutrition, health, and wellness products in Australia, New Zealand, the Asia Pacific, and North America. It provides organic tea tree oils; and distributes botanical oils, as well as supplies essential oils, hydrosols, extracts, carrier oils, and seed oils. The company also offers organic raw honey and raw honey probiotic concentrates; and contract manufacturing services. In addition, it offers medical nutrition solutions for chronic and lifestyle diseases, including Gluco Smooth for type 2 diabetes that reduces the post-meal blood sugar levels; and dietary interventions. The company was formerly known as EVE Investments Limited. Eve Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.

How the Company Makes Money

EVE Health Group Limited generates revenue through multiple streams, primarily by offering subscription-based telehealth services, which provide users with access to healthcare professionals and resources. Additionally, the company earns income from the sale of medical devices tailored for women's health, as well as licensing agreements for its proprietary health information platforms. Strategic partnerships with healthcare providers and organizations further enhance EVE's market reach and contribute to its financial stability, allowing the company to tap into broader networks and customer bases.

EVE Health Group Limited Financial Statement Overview

Summary

EVE Health Group Limited faces significant financial challenges, with declining revenues and persistent profitability issues. Despite a low leverage position, the company struggles to generate returns on equity. Cash flow improvements are noted, but operational cash flow difficulties persist.

Income Statement

EVE Health Group Limited has experienced declining revenue growth, with a notable decrease of 13.44% in the latest year. The company has consistently reported negative net profit margins, indicating ongoing profitability challenges. Gross profit margins have shown some improvement, but EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio is low at 0.03, suggesting limited leverage and a conservative capital structure. However, the return on equity is negative, indicating that the company is not generating returns on shareholders' equity. The equity ratio is relatively stable, showing a solid equity base compared to total assets.

Cash Flow

EVE Health Group Limited has shown improvement in free cash flow growth, but operating cash flow remains negative, indicating cash flow challenges. The operating cash flow to net income ratio is negative, suggesting that the company is not effectively converting its net income into cash flow. The free cash flow to net income ratio is stable at 1.0, indicating that free cash flow aligns with net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.73M	1.73M	2.13M	2.33M	2.01M	2.80M
Gross Profit	824.03K	824.03K	876.96K	827.83K	-1.00M	-713.50K
EBITDA	-1.45M	-1.43M	-1.51M	-2.18M	-4.53M	-2.79M
Net Income	-1.58M	-1.58M	-1.90M	-4.04M	-5.37M	-3.63M
Balance Sheet
Total Assets	4.12M	4.12M	2.52M	4.13M	8.07M	11.92M
Cash, Cash Equivalents and Short-Term Investments	903.42K	903.42K	106.17K	192.48K	1.10M	3.16M
Total Debt	91.28K	91.28K	74.85K	4.28K	492.39K	1.01M
Total Liabilities	572.45K	572.45K	1.30M	1.01M	1.14M	1.74M
Stockholders Equity	3.55M	3.55M	1.22M	3.12M	6.93M	10.19M
Cash Flow
Free Cash Flow	-1.62M	-1.62M	-1.11M	-1.65M	-3.80M	-2.51M
Operating Cash Flow	-1.62M	-1.62M	-1.11M	-1.65M	-3.77M	-2.24M
Investing Cash Flow	2.13M	2.13M	874.27K	498.46K	-26.05K	-263.38K
Financing Cash Flow	279.09K	279.09K	146.37K	240.69K	1.74M	529.43K

EVE Health Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
HCT	43 Neutral	AU$29.06M	34.78	―	―	6.76%	―
NGS	43 Neutral	AU$6.66M	-0.67	―	―	-21.84%	79.99%
OMG	42 Neutral	AU$7.54M	-2.78	-77.48%	―	63.30%	70.00%
EVE	41 Neutral	AU$5.41M	-1.75	-60.84%	―	-18.70%	20.83%
CCO	37 Underperform	AU$13.76M	―	-555.97%	―	88.48%	51.61%

EVE Health Group Limited Corporate Events

EVE Health Moves Into Commercial Phase With First Dyspro Prescriptions and Libbo Manufacturing Milestone

EVE Health Group has transitioned from development to early commercialisation in the December 2025 quarter, with first patient prescriptions of Dyspro™ under Australian regulatory pathways and completion of the initial commercial manufacturing run of Libbo™, which is now in national distribution and positioned for near-term prescribing via telehealth and pharmacies. The company strengthened its clinical and patient engagement infrastructure through a national telehealth patient support agreement with hubMed, launch of the Reclaim My Cycle education and research platform for women with period pain, appointment of its first Medical Science Liaison to drive prescriber education, and a $1.1 million capital raising to accelerate the rollout and regulatory progression of both flagship products, leaving it with $0.9 million in cash and signaling growing investor confidence in its commercialisation strategy.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health Group Finalises First Commercial Production of Libbo Erectile Dysfunction Treatment

EVE Health Group has completed the first commercial manufacturing run of Libbo, its oral dissolving film treatment for erectile dysfunction, and delivered inventory to a national distribution partner, moving the product from development into commercial launch. With quality-assured stock now integrated into national warehousing, logistics and fulfilment systems, and telehealth prescribing and pharmacy channels in place, the company is positioned for imminent market entry, advancing its men’s health portfolio and underpinning its broader strategy to build scalable, revenue-generating pharmaceutical offerings in the sizable and growing erectile dysfunction treatment market.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health Director Stuart Gunzburg Increases Stake with On‑Market Share Purchase

EVE Health Group Limited has disclosed a change in the shareholding of director Stuart Gunzburg, who acquired 200,000 ordinary shares in the company on 2 January 2026 via an on‑market trade for a total consideration of A$4,200. Following the transaction, Gunzburg’s direct holding remains at 7,936,508 ordinary shares, while his indirect interests through various associated entities increased to 1,180,555 ordinary shares and 1,000,000 unlisted options, signalling a modest increase in his overall equity exposure and aligning his interests more closely with shareholders, though without indicating any broader strategic shift at the company.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health Group Issues New Equity Securities as Part of Employee Incentive Scheme

EVE Health Group Limited announced the issuance of 11,300,000 new unquoted equity securities, specifically options exercisable at 6 cents and expiring on December 31, 2028. This move is part of an employee incentive scheme, which could potentially enhance employee engagement and align their interests with the company’s growth objectives.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health Group Issues New Unquoted Securities

EVE Health Group Limited has announced the issuance of 22,999,998 unquoted securities, which are options exercisable at 6 cents and set to expire on December 31, 2027. This issuance is part of a previously announced transaction, indicating strategic financial maneuvers that may impact the company’s market positioning and stakeholder interests.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health Group Successfully Passes All Resolutions at General Meeting

EVE Health Group announced that all resolutions proposed at its General Meeting on December 4, 2025, were successfully passed by a poll. This outcome supports the company’s strategic initiatives, including the ratification and approval of various securities and options, which are expected to strengthen its market position and facilitate the commercialization of its innovative pharmaceutical products.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health Group Announces Director’s Shareholding Change

EVE Health Group Limited has announced a change in the director’s interest notice for Stuart Gunzburg. The change involves an off-market transfer of 20,502,645 ordinary shares, which were previously held indirectly through CBLW Pty Ltd. This transfer is part of a Deed of Settlement, and the shares will remain under voluntary escrow until June 12, 2026. This adjustment in shareholding does not involve any cash consideration and reflects a strategic realignment of interests within the company’s leadership.

EVE Health Group Launches Innovative Products for Women’s and Men’s Health

EVE Health Group Limited has announced the launch of two innovative products: Dyspro, a fast-acting non-hormonal gummy for menstrual pain, and Libbo, a rapid-onset oral strip for erectile dysfunction. These products target the large, underserved global markets for dysmenorrhoea and erectile dysfunction, valued at US$10.92 billion and US$5.31 billion respectively. The company’s patent-pending nano-emulsion technology enhances the speed and effectiveness of these formulations. Dyspro has already been launched in Australia, with Libbo expected to follow in December, marking a significant step in the company’s commercialisation efforts.

EVE Health Group Enhances Patient Care with New Telehealth Partnership

EVE Health Group Limited has signed a Patient Support Telehealth Services Agreement with hubMed Pty Ltd to enhance care for patients using its products, Dyspro™ and Libbo™, for women’s and men’s health conditions. This agreement aims to improve continuity of care and patient confidence by providing accessible telehealth consultations with registered nurses, reinforcing the safe use of EVE’s therapies. The initiative is expected to address significant unmet needs in both women’s and men’s health, potentially improving patient outcomes and adherence to treatment.

EVE Health Group Enhances Patient Support with New Telehealth Agreement

EVE Health Group Limited has signed a Patient Support Telehealth Services Agreement with hubMed Pty Ltd to enhance care for patients using EVE’s products for women’s and men’s health conditions. This partnership aims to improve continuity of care through regular telehealth consultations, supporting patient adherence and timely clinical guidance. The initiative is expected to strengthen EVE’s market positioning by providing better patient outcomes and expanding their digital ecosystem to support product launches.

EVE Health Group Passes All AGM Resolutions

EVE Health Group announced that all resolutions presented at its Annual General Meeting were passed by a poll. This includes the adoption of the remuneration report, the re-election of a director, approval of an additional 10% capacity, and the issuance of securities under an employee incentive plan. These decisions reflect strong shareholder support and could positively impact the company’s strategic initiatives and market positioning.